New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows

First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.

  News   Nov 27, 2025   0   3  Add to Reading List
New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows
A woman works on a lung cancer vaccine on October 1, 2023 at the Ose Immunotherapeutics laboratory in Nantes. (photo credit: LOIC VENANCE/AFP via Getty Images)
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow